Aspira Women's Health Inc. (AWH)
USD 0.1
(1.8%)
USD 0.1
(1.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -331 Thousand USD | 102.69% |
| 2022 | -9.47 Million USD | 71.35% |
| 2021 | -33.07 Million USD | -187.29% |
| 2020 | -11.51 Million USD | -10.58% |
| 2019 | -10.41 Million USD | -32.14% |
| 2018 | -7.87 Million USD | -103.43% |
| 2017 | -3.87 Million USD | -14.15% |
| 2016 | -3.39 Million USD | 81.74% |
| 2015 | -18.57 Million USD | 15.01% |
| 2014 | -21.85 Million USD | 23.03% |
| 2013 | -28.39 Million USD | -311.51% |
| 2012 | -6.9 Million USD | 55.41% |
| 2011 | -15.47 Million USD | 13.6% |
| 2010 | -17.91 Million USD | -373.08% |
| 2009 | 6.56 Million USD | -60.03% |
| 2008 | 16.41 Million USD | -22.02% |
| 2007 | 21.05 Million USD | 169.87% |
| 2006 | 7.8 Million USD | 21.42% |
| 2005 | 6.42 Million USD | 207.16% |
| 2004 | -5.99 Million USD | -506.78% |
| 2003 | -988 Thousand USD | 95.58% |
| 2002 | -22.32 Million USD | 51.15% |
| 2001 | -45.7 Million USD | 57.2% |
| 2000 | -106.79 Million USD | -10536.75% |
| 1999 | -1 Million USD | 85.66% |
| 1998 | -7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -726 Thousand USD | -384.71% |
| 2024 Q2 | 1.39 Million USD | 292.56% |
| 2023 Q1 | -4.02 Million USD | 57.56% |
| 2023 Q2 | -1.93 Million USD | 51.98% |
| 2023 Q3 | -2.76 Million USD | -43.09% |
| 2023 Q4 | 255 Thousand USD | 109.23% |
| 2023 FY | 255 Thousand USD | 102.69% |
| 2022 Q4 | -9.47 Million USD | 45.6% |
| 2022 FY | -9.47 Million USD | 71.35% |
| 2022 Q2 | -17.01 Million USD | 26.23% |
| 2022 Q1 | -23.07 Million USD | 30.24% |
| 2022 Q3 | -17.41 Million USD | -2.33% |
| 2021 Q3 | -41.48 Million USD | 15.93% |
| 2021 Q4 | -33.07 Million USD | 20.27% |
| 2021 FY | -33.07 Million USD | -187.29% |
| 2021 Q1 | -54.45 Million USD | -373.03% |
| 2021 Q2 | -49.33 Million USD | 9.4% |
| 2020 FY | -11.51 Million USD | -10.58% |
| 2020 Q1 | -6.88 Million USD | 33.84% |
| 2020 Q2 | -8.73 Million USD | -26.79% |
| 2020 Q3 | -16.25 Million USD | -86.09% |
| 2020 Q4 | -11.51 Million USD | 29.16% |
| 2019 FY | -10.41 Million USD | -32.14% |
| 2019 Q2 | -14.79 Million USD | -212.07% |
| 2019 Q1 | -4.74 Million USD | 39.84% |
| 2019 Q3 | -13.29 Million USD | 10.11% |
| 2019 Q4 | -10.41 Million USD | 21.7% |
| 2018 Q4 | -7.87 Million USD | 23.0% |
| 2018 Q1 | -1.48 Million USD | 61.71% |
| 2018 Q2 | -12.56 Million USD | -747.0% |
| 2018 FY | -7.87 Million USD | -103.43% |
| 2018 Q3 | -10.23 Million USD | 18.54% |
| 2017 Q3 | -6.03 Million USD | -40.24% |
| 2017 Q2 | -4.3 Million USD | 29.68% |
| 2017 FY | -3.87 Million USD | -14.15% |
| 2017 Q4 | -3.87 Million USD | 35.8% |
| 2017 Q1 | -6.11 Million USD | -80.31% |
| 2016 FY | -3.39 Million USD | 81.74% |
| 2016 Q1 | -13.01 Million USD | 29.96% |
| 2016 Q2 | -9.12 Million USD | 29.88% |
| 2016 Q3 | -6.19 Million USD | 32.11% |
| 2016 Q4 | -3.39 Million USD | 45.22% |
| 2015 Q4 | -18.57 Million USD | 22.27% |
| 2015 FY | -18.57 Million USD | 15.01% |
| 2015 Q3 | -23.9 Million USD | -119.74% |
| 2015 Q2 | -10.87 Million USD | 36.91% |
| 2015 Q1 | -17.24 Million USD | 21.13% |
| 2014 Q1 | -24.88 Million USD | 12.37% |
| 2014 Q3 | -15.65 Million USD | 25.73% |
| 2014 FY | -21.85 Million USD | 23.03% |
| 2014 Q2 | -21.08 Million USD | 15.29% |
| 2014 Q4 | -21.85 Million USD | -39.62% |
| 2013 Q2 | -15.28 Million USD | -223.31% |
| 2013 Q3 | -13.49 Million USD | 11.7% |
| 2013 Q4 | -28.39 Million USD | -110.39% |
| 2013 FY | -28.39 Million USD | -311.51% |
| 2013 Q1 | -4.72 Million USD | 31.49% |
| 2012 Q3 | -9.32 Million USD | 17.38% |
| 2012 Q2 | -11.29 Million USD | 12.14% |
| 2012 Q1 | -12.85 Million USD | 16.97% |
| 2012 Q4 | -6.9 Million USD | 26.02% |
| 2012 FY | -6.9 Million USD | 55.41% |
| 2011 FY | -15.47 Million USD | 13.6% |
| 2011 Q1 | -28.22 Million USD | -57.58% |
| 2011 Q3 | -20.22 Million USD | 16.71% |
| 2011 Q4 | -15.47 Million USD | 23.49% |
| 2011 Q2 | -24.28 Million USD | 13.97% |
| 2010 Q2 | -16.58 Million USD | 35.56% |
| 2010 FY | -17.91 Million USD | -373.08% |
| 2010 Q1 | -25.73 Million USD | -492.29% |
| 2010 Q4 | -17.91 Million USD | -34.77% |
| 2010 Q3 | -13.29 Million USD | 19.85% |
| 2009 Q4 | 6.56 Million USD | -23.19% |
| 2009 Q1 | 9.25 Million USD | -43.63% |
| 2009 FY | 6.56 Million USD | -60.03% |
| 2009 Q3 | 8.54 Million USD | -11.92% |
| 2009 Q2 | 9.69 Million USD | 4.8% |
| 2008 Q3 | 26.95 Million USD | 14.83% |
| 2008 FY | 16.41 Million USD | -22.02% |
| 2008 Q1 | 20.44 Million USD | -2.89% |
| 2008 Q2 | 23.47 Million USD | 14.84% |
| 2008 Q4 | 16.41 Million USD | -39.11% |
| 2007 FY | 21.05 Million USD | 169.87% |
| 2007 Q1 | 13.63 Million USD | 74.79% |
| 2007 Q2 | 19 Million USD | 39.36% |
| 2007 Q3 | 9.11 Million USD | -52.04% |
| 2007 Q4 | 21.05 Million USD | 131.01% |
| 2006 Q3 | 20.22 Million USD | 51.93% |
| 2006 FY | 7.8 Million USD | 21.42% |
| 2006 Q1 | 8.31 Million USD | 29.48% |
| 2006 Q2 | 13.31 Million USD | 60.05% |
| 2006 Q4 | 7.8 Million USD | -61.44% |
| 2005 Q2 | 7.87 Million USD | 1043.35% |
| 2005 Q1 | -835 Thousand USD | 86.07% |
| 2005 Q3 | 1.41 Million USD | -82.01% |
| 2005 Q4 | 6.42 Million USD | 353.35% |
| 2005 FY | 6.42 Million USD | 207.16% |
| 2004 Q2 | 9.39 Million USD | 292.56% |
| 2004 FY | -5.99 Million USD | -506.78% |
| 2004 Q4 | -5.99 Million USD | -134.91% |
| 2004 Q1 | 2.39 Million USD | 342.11% |
| 2004 Q3 | 17.17 Million USD | 82.89% |
| 2003 Q2 | -14.93 Million USD | 34.64% |
| 2003 Q3 | -2.28 Million USD | 84.7% |
| 2003 Q4 | -988 Thousand USD | 56.78% |
| 2003 Q1 | -22.85 Million USD | -2.37% |
| 2003 FY | -988 Thousand USD | 95.58% |
| 2002 Q3 | -29.38 Million USD | 32.64% |
| 2002 Q1 | -42.64 Million USD | 6.71% |
| 2002 FY | -22.32 Million USD | 51.15% |
| 2002 Q4 | -22.32 Million USD | 24.01% |
| 2002 Q2 | -43.62 Million USD | -2.29% |
| 2001 Q4 | -45.7 Million USD | 10.43% |
| 2001 Q3 | -51.03 Million USD | 33.15% |
| 2001 Q2 | -76.34 Million USD | 22.36% |
| 2001 FY | -45.7 Million USD | 57.2% |
| 2001 Q1 | -98.32 Million USD | 7.93% |
| 2000 Q4 | -106.79 Million USD | -527.01% |
| 2000 Q3 | -17.03 Million USD | 0.0% |
| 2000 FY | -106.79 Million USD | -10536.75% |
| 1999 FY | -1 Million USD | 85.66% |
| 1998 FY | -7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 99.161% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 94.403% |
| Biodesix, Inc. | 34.3 Million USD | 100.965% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 94.289% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 73.369% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 73.369% |
| Bionano Genomics, Inc. | 34.88 Million USD | 100.949% |
| CareDx, Inc | -47.97 Million USD | 99.31% |
| Check-Cap Ltd. | -24.75 Million USD | 98.663% |
| Castle Biosciences, Inc. | -83.53 Million USD | 99.604% |
| DarioHealth Corp. | -7.54 Million USD | 95.615% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.017% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 99.599% |
| Guardant Health, Inc. | 220.22 Million USD | 100.15% |
| ICON Public Limited Company | 3.56 Billion USD | 100.009% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 100.067% |
| Illumina, Inc. | 1.21 Billion USD | 100.027% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 93.907% |
| iSpecimen Inc. | -2.14 Million USD | 84.586% |
| Standard BioTools Inc. | 46.5 Million USD | 100.712% |
| MDxHealth SA | 18.88 Million USD | 101.753% |
| 23andMe Holding Co. | -141.37 Million USD | 99.766% |
| Medpace Holdings, Inc. | -103.32 Million USD | 99.68% |
| Myriad Genetics, Inc. | 88.1 Million USD | 100.376% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 194.611% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 86.432% |
| NeoGenomics, Inc. | 269.19 Million USD | 100.123% |
| Neogen Corporation | 735.62 Million USD | 100.045% |
| Inotiv, Inc. | 382.14 Million USD | 100.087% |
| Natera, Inc. | -200.1 Million USD | 99.835% |
| OpGen, Inc. | 11.89 Million USD | 102.783% |
| OPKO Health, Inc. | 230.68 Million USD | 100.143% |
| Psychemedics Corporation | 334 Thousand USD | 199.102% |
| Prenetics Global Limited | -43.33 Million USD | 99.236% |
| Prenetics Global Limited | -43.33 Million USD | 99.236% |
| Precipio, Inc. | -386 Thousand USD | 14.249% |
| Personalis, Inc. | -8.02 Million USD | 95.874% |
| RadNet, Inc. | 1.14 Billion USD | 100.029% |
| Sera Prognostics, Inc. | -2.02 Million USD | 83.63% |
| Sotera Health Company | 2.02 Billion USD | 100.016% |
| Neuronetics, Inc. | 2.79 Million USD | 111.834% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 97.842% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 97.842% |
| Trinity Biotech plc | 63.73 Million USD | 100.519% |
| T2 Biosystems, Inc. | 33.8 Million USD | 100.979% |
| Twist Bioscience Corporation | -192.4 Million USD | 99.828% |
| Exagen Inc. | -12.77 Million USD | 97.408% |